## UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

JOHN GUERRA, Plaintiff,

**Civil Action No.: 4:17-cv-00031** 

v.

JOHNSON & JOHNSON and ETHICON, INC.,

**JURY TRIAL DEMANDED** 

Defendants.

### **COMPLAINT**

Come now Plaintiff, John Guerra by and through undersigned counsel, and bring this action against Defendants Ethicon, Inc. and Johnson & Johnson (hereinafter "Defendants"), and allege as follows:

#### **Parties**

- 1. Plaintiff is, and was, at all relevant times, a citizen and residents of California and the United States.
- 2. Defendant Johnson & Johnson ("J&J") is a corporation incorporated in New Jersey, and according to its website, the world's largest and most diverse medical device and diagnostics Company, with its principal place of business located at One Johnson & Johnson Plaza, New Brunswick, New Jersey. Defendant J&J is a citizen of New Jersey.
- 3. Defendant J&J organizes its subsidiary businesses into individual Business Units to coordinate the development, manufacture, testing, marketing promotion, training, distribution and sale of its products, including but not limited to its hernia repair mesh products. Within J&J there are three sectors: medical devices and diagnostics, pharmaceutical, and consumer. Within

the medical devices and diagnostic sector are "Business Units" including the "Ethicon Franchise." The Ethicon Franchise was charged by J&J with the design, development, promotion, marketing, testing, training, distribution and sale of the hernia repair mesh products at issue in this case. The Company Group Chairman and Worldwide Franchise Chairman for the Ethicon Franchise, Gary Pruden, are employed by J&J. The companies which comprise the Ethicon Franchise are thus controlled by J&J and include, but are not limited to, Ethicon Inc.

- 4. Defendant Ethicon, Inc. is a wholly owned subsidiary of Defendant Johnson & Johnson. Defendant Ethicon, Inc. is a corporation incorporated in the State of New Jersey with its principal place of business in Somerville, New Jersey. Ethicon is a citizen of New Jersey. Ethicon is authorized and registered to transact business within the State of California.
- 5. Ethicon is a medical device company involved in the research, development, testing, manufacture, production, marketing, promotion and/or sale of medical devices including Physiomesh (hereinafter may be referred to as the "product").
- 6. J&J, directly and/or through the actions of Ethicon, Inc., has at all pertinent times been responsible for the research, development, testing, manufacture, production, marketing, promotion, distribution and/or sale of Physiomesh.
- 7. Defendants are individually, jointly and severally liable to Plaintiff for damages suffered by Plaintiff John Guerra arising from the Defendants' design, manufacture, marketing, labeling, distribution, sale and placement of its defective mesh products at issue in the instant action, effectuated directly and indirectly through their respective agents, servants, employees and/or owners, all acting within the course and scope of their representative agencies, services, employments and/or ownership.

8. Defendants are vicariously liable for the acts and/or omissions of its employees and/or agents who were at all times relevant hereto acting on behalf of Defendants and within the scope of their employment or agency with Defendants.

#### **Jurisdiction and Venue**

9. This Court has subject-matter jurisdiction over this action pursuant to 28 U.S.C. \$1332(a) based on complete diversity of citizenship between Plaintiff and all Defendants. The amount in controversy exceeds \$75,000.

#### **Facts Common To All Counts**

- 10. Plaintiff John Guerra was implanted with a Physiomesh (25CM x 20CM) and (5CM x 8CM) device at Providence Little Company of Mary Medical Center in Torrance, California to attempt repair of an incisional hernia.
- 11. Defendants manufactured, sold, and/or distributed the Physiomesh device to Plaintiff, through his doctors, to be used for treatment of hernia repair.
- 12. On or about January 1, 2014, Plaintiff John Guerra underwent surgery at Providence Little Company of Mary Medical Center in Torrance, California for recurrent abdominal surgery after his Physiomesh device. Mr. Guerra developed complication of chronic seroma postoperative and underwent excision of the seroma cavity multiple times which did reduce but did not completely destroy his seroma.
- 13. Defendants were responsible for the research, design, development, testing, manufacture, production, marketing, promotion, distribution and sale of Physiomesh including providing the warnings and instructions concerning the product.

- 14. Among the intended purposes for which Defendants designed, manufactured and sold Physiomesh was use by surgeons for hernia repair surgeries, the purpose for which the Physiomesh was implanted in Plaintiff John Guerra.
- 15. Defendants represented to Plaintiff and Plaintiff's physicians that Physiomesh was a safe and effective product for hernia repair.
- Defendants' Physiomesh was defectively designed and/or manufactured, was not reasonably safe for its intended use in hernia repair, and the risks of the design outweighed any potential benefits associated with the design. As a result of the defective design and/or manufacture of the Physiomesh, there was an unreasonable risk of severe adverse reactions to the mesh or mesh components including: chronic pain; recurrence of hernia; foreign body response; rejection; infection; inadequate or failure of incorporation/ingrowth; migration; scarification; deformation of mesh; improper wound healing; excessive and chronic inflammation; adhesion to internal organs; erosion; abscess; fistula formation; granulomatous response; seroma formation; nerve damage; tissue damage and/or death; and other complications.
- 17. Physiomesh has a unique design incorporating five (5) distinct layers: two layers of polyglecaprone-25 ("Monocryl") film covering two underlying layers of polydioxanone film ("PDS"), which in turn coat a polypropylene mesh. This design is not used in any other hernia repair product sold in the United States. The multi-layer coating was represented and promoted by the Defendants to prevent or minimize adhesion and inflammation and to facilitate incorporation of the mesh into the body, but it did not. Instead, the multi-layer coating prevented adequate incorporation of the mesh into the body and caused or contributed to an intense inflammatory and chronic foreign body response resulting in an adverse tissue reaction including

migration and damage to surrounding tissue in the form of sclerotic, granulomatous and/or fibrotic tissue and improper healing.

- 18. When affixed to the body's tissue, the impermeable multi-layer coating of the Physiomesh prevents fluid escape, which leads to seroma formation, and which in turn can cause infection, abscess formation and other complications.
- 19. The multi-layer coating provides a breeding ground for bacteria in which the bacteria cannot be eliminated by the body's immune response, which allows infection to proliferate.
- 20. The multi-layer coating of Defendants' Physiomesh is cytotoxic, immunogenic, and not biocompatible, which causes or contributes to complications such as delayed wound healing, inflammation, foreign body response, rejection, infection, and other complications.
- 21. Defendants knew or should have known of the cytotoxic and immunogenic properties of the multi-layer coating of the Physiomesh prior to introducing it into the stream of commerce.
- 22. The polypropylene mesh portion of the Physiomesh was insufficient to withstand normal abdominal forces, which resulted in recurrent hernia formation and/or rupture and deformation of the mesh itself.
- 23. When the multi-layer coating of the Physiomesh is disrupted and/or degrades, the "naked" polypropylene mesh is exposed to the adjoining tissue and viscera, and can become adhered to organs, and cause damage to organs, and potentiate fistula formation.
- 24. These manufacturing and design defects associated with the Physiomesh were directly and proximately related to the injuries suffered by Plaintiff John Guerra.

- 25. Neither Plaintiff John Guerra nor his implanting physician were adequately warned or informed by Defendants of the defective and dangerous nature of Physiomesh. Moreover, neither Plaintiff John Guerra nor his implanting physician were adequately warned or informed by Defendants of the risks associated with the Physiomesh or the frequency, severity, or duration of such risks.
- 26. The Physiomesh implanted in Plaintiff John Guerra failed to reasonably perform as intended. The mesh failed, caused serious injury and portions of the mesh had to be surgically removed via invasive surgery, and necessitated additional invasive surgery to repair the hernia that the Physiomesh was initially implanted to treat.
- 27. Plaintiff John Guerra's severe adverse reaction, and the necessity for surgical removal of the Physiomesh, directly and proximately resulted from the defective and dangerous condition of the product and Defendants' defective and inadequate warnings about the risks associated with the product, and the frequency, severity and duration of such risks. Plaintiff John Guerra has suffered, and will continue to suffer, physical injury and pain and mental anguish, permanent and severe scarring and disfigurement, and has incurred substantial medical bills and other expenses, resulting from the defective and dangerous condition of the product and from Defendants' defective and inadequate warnings about the risks associated with the product.

# COUNT I Strict Product Liability: Defective Design

- 28. Plaintiffs incorporate herein by reference the allegations in paragraphs 13 through 29 as if fully set forth herein.
- 29. At the time the Physiomesh that was implanted in Plaintiff John Guerra's body, the product was defectively designed. As described above, there was an unreasonable risk that

the product would not perform safely and effectively for the purposes for which it was intended, and Defendants failed to design against such dangers, and failed to provide adequate warnings and instructions concerning these risks.

- 30. Defendants expected and intended the Physiomesh product to reach users such as Plaintiff in the condition in which the product was sold.
- 31. The implantation of Physiomesh in Plaintiff's body was medically reasonable, and was a type of use that Defendants intended and foresaw when it designed, manufactured and sold the product.
- 32. The risks of the Physiomesh design significantly outweigh any benefits that Defendants contend could be associated with the product's design. The multi-layer coating, which is not used in any other hernia mesh product sold in the United States, prevents tissue from incorporating into the mesh, leading to encapsulation, deformation, scarification and contraction, migration, erosion and rejection. The impermeable multi-layer coating leads to seroma formation, and provides a breeding ground for infection, and protects bacteria from being eliminated by the body's natural immune response.
- 33. The multi-layer coating of the Physiomesh, which was marketed, promoted and intended as a barrier against adhesion to the internal organs, was only temporary; it was expected and intended to degrade over time inside the body. Thus, this coating prevented tissue ingrowth in the short term, and degraded in the long-term, eventually leaving the "naked" polypropylene mesh exposed to the internal viscera and tissues. The degradation of this multi-layer coating caused or exacerbated an intense inflammatory and foreign body reaction. Once exposed to the viscera, the polypropylene mesh will inevitably adhere to the viscera, initiating a cascade of adverse consequences. Any purported beneficial purpose of the multi-layer coating (to prevent

adhesion to the internal viscera and organs) was non-existent; the product provided no benefit while substantially increasing the risks to the patient.

- 34. The polypropylene mesh within the defective multi-layer coating of the Physiomesh was in itself dangerous and defective, particularly when used in the manner intended by Defendants in the Physiomesh. When implanted adjacent to the intestines and other internal organs, as Defendants intended for Physiomesh, polypropylene mesh is unreasonably susceptible to adhesion, bowel perforation or erosion, fistula formation and bowel strangulation or hernia incarceration, and other injuries.
- 35. The polypropylene mesh used in the Physiomesh device was insufficient in strength to withstand the internal forces of the abdomen after implantation, which made the device susceptible to rupture and/or deformation, as occurred with the Physiomesh implanted in Mr. Guerra.
- 36. The appropriate treatment for complications associated with Physiomesh involves additional invasive surgery to remove the mesh from the body, thus eliminating any purported benefit that the mesh was intended to provide to the patient.
- 37. Physiomesh was designed and intended for intraperitoneal implantation, which involved the product being implanted in contact with the intestines and/or other internal organs, which unnecessarily increased the risks of adhesion, erosion, fistula formation, and other injuries.
- 38. At the time the Physiomesh was implanted in Plaintiff, there were safer feasible alternative designs for hernia mesh products that would have prevented the injuries he suffered.
- 39. The Physiomesh product cost significantly more than competitive products because of its unique multi-layer coating, even though the multi-layer coating provided no

benefit to consumers, and increased the risks to patients implanted with these devices.

- 40. The Physiomesh implanted in Plaintiff failed to reasonably perform as intended, and had to be surgically removed necessitating further invasive surgery to repair the very issue that the product was intended to repair, and thus provided no benefit to him.
- 41. As a direct and proximate result of the defective and unreasonably dangerous condition of the product, Plaintiff suffered injuries and damages as summarized herein.

### COUNT II Strict Product Liability: Failure to Warn

- 42. Plaintiffs incorporate herein by reference the allegations in paragraphs 13 through 29 as if fully set forth herein.
- 43. At the time the Physiomesh that was implanted in Plaintiff's body, the warnings and instructions provided by Defendants for the Physiomesh were inadequate and defective. As described above, there was an unreasonable risk that the product would not perform safely and effectively for the purposes for which it was intended, and Defendants failed to design and/or manufacture against such dangers, and failed to provide adequate warnings and instructions concerning these risks.
- 44. Defendants expected and intended the Physiomesh product to reach users such as Plaintiff in the condition in which the product was sold.
- 45. Plaintiff and his physicians were unaware of the defects and dangers of Physiomesh, and were unaware of the frequency, severity and duration of the defects and risks associated with the Physiomesh.
- 46. The Defendants' Instructions for Use provided with the Physiomesh expressly understates and misstates the risks known to be associated specifically with the Physiomesh by

stating that "Potential adverse reactions are those typically associated with surgically implantable materials." No other surgical mesh sold in the United States – and no other "surgically implantable material" – suffers the same serious design flaws as Physiomesh. No other device or material contains the dangerous and defective multi-layer coating, which itself causes or increases the risks of numerous complications, including prevention of incorporation, increased risk of seroma formation, immunologic response, increased risk for infection, and increased inflammatory reaction and foreign body response. Defendants provided no warning to physicians about the risks or increased risks specifically associated with the unique design of the Physiomesh.

- 47. The Defendants' Instructions for Use for the Physiomesh failed to adequately warn Plaintiff's physicians of numerous risks which Defendants knew or should have known were associated with the Physiomesh, including the risks of the product's inhibition of tissue incorporation, pain, immunologic response, dehiscence, encapsulation, rejection, migration, scarification, shrinkage/contraction, adhesion to internal organs and viscera, erosion through adjacent tissue and viscera, intestinal obstruction, failure of repair/hernia recurrence, hernia incarceration or strangulation, or rupture of the mesh.
- 48. Defendants failed to adequately train or warn Plaintiff or her physicians about the necessity for invasive surgical intervention in the event of complications, or how to properly treat such complications when they occurred.
- 49. Defendants failed to adequately warn Plaintiff or his physicians that the necessary surgical removal of the Physiomesh in the event of complications would leave the hernia unrepaired, and would necessitate further medical treatment to attempt to repair the same hernia that the failed Physiomesh was intended to treat.

- 50. Defendants represented to physicians, including Plaintiff's physician, that the multi-layer coating would prevent or reduce adhesion, and expressly intended for the Physiomesh to be implanted in contact with the intestines and internal organs and marketed and promoted the product for said purpose. Defendants failed to warn physicians that the multi-layer coating prevented tissue ingrowth, which is the desired biologic response to an implantable mesh device. Defendants failed to warn physicians that the multi-layer coating was only temporary and therefore at best would provide only a temporary adhesion barrier, and when the coating inevitably degraded, the exposed polypropylene would become adhered to the organs or tissue.
- 51. With respect to the complications that were listed in the Defendants' warnings, Defendants provided no information or warning regarding the frequency, severity and duration of those complications, even though the complications associated with Physiomesh were more frequent, more severe and lasted longer than those with safer feasible alternative hernia repair treatments.
- 52. If Plaintiff and/or his physicians had been properly warned of the defects and dangers of Physiomesh, and of the frequency, severity and duration of the risks associated with the Physiomesh, Plaintiff would not have consented to allow the Physiomesh to be implanted in his body, and Plaintiff physicians would not have implanted the Physiomesh in Plaintiff.
- 53. As a direct and proximate result of the inadequate and defective warnings and instructions, Plaintiff suffered injuries and damages as summarized herein.

# COUNT III Negligence

54. Plaintiffs incorporate herein by reference the allegations of paragraphs 13 through 56 as if fully set forth herein.

- 55. Defendants had a duty to use reasonable care in designing, testing, inspecting, manufacturing, packaging, labeling, marketing, distributing, training, and preparing written instructions and warnings for Physiomesh, but failed to do so.
- 56. Defendants knew, or in the exercise of reasonable care should have known, that Physiomesh was defectively and unreasonably designed and/or manufactured, and was unreasonably dangerous and likely to injure patients in whom Physiomesh was implanted. Defendants knew or should have known that Plaintiff and Plaintiff's physicians were unaware of the dangers and defects inherent in the Physiomesh.
- As a direct and proximate result of Defendants' negligence in designing, testing, inspecting, manufacturing, packaging, labeling, marketing, distributing, training and preparing written instructions and warnings for Physiomesh, Plaintiffs suffered injuries and damages as summarized herein.

# Count IV Punitive Damages

- 58. Plaintiffs incorporate herein by reference the allegations in paragraphs 13 through 62 as if fully set forth herein.
- 59. Defendants failed to adequately test and study the Physiomesh to determine and ensure that the product was safe and effective prior to releasing the product for sale for permanent human implantation, and Defendants continued to manufacture and sell Physiomesh after obtaining knowledge and information that the product was defective and unreasonably unsafe. Even though Defendants has other hernia repair mesh devices that do not present the same risks as the Physiomesh, Defendants developed, designed and sold Physiomesh, and continue to do so, because the Physiomesh has a significantly higher profit margin than other hernia repair products. Defendants were aware of the probable consequences of implantation of

Case 1:17-cv-04298 Document 1 Filed 06/14/17 Page 13 of 13 PageID: 13

the dangerous and defective Physiomesh, including the risk of failure and serious injury, such as

suffered by Plaintiff. Defendants willfully and recklessly failed to avoid those consequences, and

in doing so, Defendants acted intentionally, maliciously and recklessly with regard the safety of

those persons who might foreseeably have been harmed by the Physiomesh product, including

Plaintiffs, justifying the imposition of punitive damages.

WHEREFORE, as a result of the acts and omissions and conduct of Defendants set forth

herein, Plaintiff John Guerra is entitled to recover for his personal injuries; past, present, and

future medical and related expenses; and past, present and future mental and physical pain and

suffering; Plaintiffs should be awarded punitive damages; and Plaintiffs should recover any other

relief, monetary or equitable, to which they are entitled.

Plaintiffs demand trial by jury, judgment against Defendants, jointly and severally, for

compensatory and punitive damages in an amount not less than \$75,000, as well as costs,

attorney fees, interest, and any other relief, monetary or equitable, to which they are entitled.

Dated: June 14, 2017

By: /s/ Nicholas R. Farnolo\_\_

Nicholas R. Farnolo

NAPOLI SHKOLNIK, PLLC

400 Broadhollow Road Melville, New York 11747

212-397-1000

Counsel for Plaintiff

JS 44 (Rev. 06/17)

### Case 1:17-cv-04298 Decument 10 V Filed 06/14/17 Page 1 of 1 PageID: 14

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS				DEFENDAN	ΓS				
(b) County of Residence of First Listed Plaintiff  (EXCEPT IN U.S. PLAINTIFF CASES)  (c) Attorneys (Firm Name, Address, and Telephone Number)			County of Residence of First Listed Defendant  (IN U.S. PLAINTIFF CASES ONLY)  NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.  Attorneys (If Known)						
II. BASIS OF JURISDI	CTION (Place an "X" in O	ne Box Only)	III. CI	TIZENSHIP OF	PRINCIP	AL PARTIES	(Place an "X" in On	ne Box fo	or Plaintif
□ 1 U.S. Government Plaintiff	☐ 3 Federal Question (U.S. Government)		(	For Diversity Cases Only			and One Box for I Principal Place	-	
☐ 2 U.S. Government Defendant	☐ 4 Diversity (Indicate Citizenshi)	ip of Parties in Item III)	Citize	n of Another State		Incorporated and I of Business In A		<b>□</b> 5	<b>□</b> 5
				n or Subject of a reign Country	<b>3 3 3</b>	Foreign Nation		□ 6	<b>1</b> 6
IV. NATURE OF SUIT	(Place an "X" in One Box On	ly)				k here for: Nature	of Suit Code Desc	riptions	3.
CONTRACT		RTS		RFEITURE/PENALTY		NKRUPTCY	OTHER ST		LS
<ul> <li>□ 110 Insurance</li> <li>□ 120 Marine</li> <li>□ 130 Miller Act</li> <li>□ 140 Negotiable Instrument</li> <li>□ 150 Recovery of Overpayment &amp; Enforcement of Judgment</li> <li>□ 151 Medicare Act</li> <li>□ 152 Recovery of Defaulted Student Loans (Excludes Veterans)</li> <li>□ 153 Recovery of Overpayment of Veteran's Benefits</li> <li>□ 160 Stockholders' Suits</li> <li>□ 190 Other Contract</li> <li>□ 195 Contract Product Liability</li> <li>□ 196 Franchise</li> </ul> REAL PROPERTY <ul> <li>□ 210 Land Condemnation</li> <li>□ 220 Foreclosure</li> <li>□ 230 Rent Lease &amp; Ejectment</li> <li>□ 240 Torts to Land</li> <li>□ 245 Tort Product Liability</li> <li>□ 290 All Other Real Property</li> </ul>	PERSONAL INJURY  □ 310 Airplane □ 315 Airplane Product Liability □ 320 Assault, Libel & Slander □ 330 Federal Employers' Liability □ 340 Marine □ 345 Marine Product Liability □ 350 Motor Vehicle □ 700 Product Liability □ 360 Other Personal Injury □ 362 Personal Injury □ 440 Other Civil Rights □ 441 Voting □ 442 Employment □ 443 Housing/ Accommodations □ 445 Amer. w/Disabilities - Employment □ 446 Amer. w/Disabilities - Other □ 448 Education	PERSONAL INJURY  365 Personal Injury - Product Liability  367 Health Care/ Pharmaceutical Personal Injury Product Liability  368 Asbestos Personal Injury Product Liability  PERSONAL PROPER  370 Other Fraud  371 Truth in Lending  380 Other Personal Property Damage Product Liability  PRISONER PETITION  Habeas Corpus: 463 Alien Detainee 510 Motions to Vacate Sentence 530 General 535 Death Penalty Other: 540 Mandamus & Othe 550 Civil Rights 555 Prison Condition 560 Civil Detainee - Conditions of Confinement	- 69	5 Drug Related Seizure of Property 21 USC 88 0 Other  LABOR 0 Fair Labor Standards Act 0 Labor/Management Relations 0 Railway Labor Act 1 Family and Medical Leave Act 0 Other Labor Litigation 1 Employee Retirement Income Security Act  IMMIGRATION 2 Naturalization Applicat 5 Other Immigration Actions	423 Wit 28   PROPH   820 Cop   830 Pate   835 Pate   Nev   840 Time   862 Blae   863 DIV   864 SSI   865 RSI   870 Tax   or 1   871 IRS   26	CRTY RIGHTS Dyrights ent ent - Abbreviated v Drug Application demark L SECURITY (1395ff) ck Lung (923) VC/DIWW (405(g)) D Title XVI	□ 375 False Clain □ 376 Qui Tam (3	portionm Banking Influence ganizatic Credit FV Commod Intory Act al Acts Influence Inf	ed and ons lities/ tions eers ation cedure
	moved from 3		J 4 Rein Reop	ened Ano	nsferred from other District	☐ 6 Multidistr Litigation Transfer	ı - Li	Iultidist itigatior rect File	n -
VI. CAUSE OF ACTION		tute under which you are	re filing (L	(spec			Di	root Fill	
VII. REQUESTED IN COMPLAINT:	CHECK IF THIS UNDER RULE 2	IS A <b>CLASS ACTION</b> 3, F.R.Cv.P.	) Di	EMAND \$		CHECK YES only JURY DEMAND:		omplain □No	ıt:
VIII. RELATED CASI IF ANY	(See instructions):	JUDGE			DOCK	ET NUMBER			
DATE		SIGNATURE OF ATT	TORNEY C	F RECORD					
FOR OFFICE USE ONLY									
RECEIPT# AM	MOUNT	APPLYING IFP		JUDGE	E	MAG. JUI	OGE		

U	NITED	<b>STATES</b>	DISTRICT	Court
Company to the contract of the				

ONITED STATES DISTRICT COURT for the				
District of				
Plaintiff V. Defendant	) ) ) Civil Action No. ) )			
SUMMONS II	N A CIVIL ACTION			
To: (Defendant's name and address)				
A lawsuit has been filed against you.  Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:				
If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.  **CLERK OF COURT**				
Date:	Signature of Clerk or Deputy Clerk			

AO 440 (Rev. 12/09) Summons in a Civil Action (Page 2)

Civil Action No.

### PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

	This summons for (nar	me of individual and title, if any)			
was re	ceived by me on (date)				
	☐ I personally served	I the summons on the individual a	t (place)		
	-		on (date)	; or	
	☐ I left the summons	at the individual's residence or u	sual place of abode with (name)		
		, a person o	f suitable age and discretion who resid	les there,	
	on (date)	, and mailed a copy to t	he individual's last known address; or		
	☐ I served the summo	ons on (name of individual)		, ,	who is
	designated by law to	accept service of process on beha	If of (name of organization)		
			on (date)	; or	
	☐ I returned the sum	mons unexecuted because			; or
	☐ Other ( <i>specify</i> ):				
	My fees are \$	for travel and \$	for services, for a total of \$		
	I declare under penalt	y of perjury that this information	is true.		
Date:					
			Server's signature		
			Printed name and title		
			1 riniea name ana titie		
			g		
			Server's address		

Additional information regarding attempted service, etc:

Tio Tio (teet. 12/07) Summons in a Civil Netion	
UNITED STATES I	
Distric	t of
Plaintiff  V.  Defendant  SUMMONS IN A  To: (Defendant's name and address)	Civil Action No.
A lawsuit has been filed against you.	
Within 21 days after service of this summons on you are the United States or a United States agency, or an officer of P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer the Federal Rules of Civil Procedure. The answer or motion rules whose name and address are:	er to the attached complaint or a motion under Rule 12 of

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

	CLERK OF COURT
Date:	
	Signature of Clerk or Deputy Clerk

AO 440 (Rev. 12/09) Summons in a Civil Action (Page 2)

Civil Action No.

### PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

	This summons for (nan	ne of individual and title, if any)					
was re	ceived by me on (date)	·					
	☐ I personally served	the summons on the individual a	at (place)				
			on (date)	; or			
	☐ I left the summons	at the individual's residence or u					
	, a person of suitable age and discretion who resides there,						
	on (date)	, and mailed a copy to	the individual's last known address; or				
	☐ I served the summe	ons on (name of individual)			, who is		
	designated by law to	accept service of process on beha	alf of (name of organization)				
			on (date)	; or			
	☐ I returned the sum	mons unexecuted because			; or		
	☐ Other (specify):						
	My fees are \$	for travel and \$	for services, for a total of \$				
			• .				
I declare under penalty of perjury that this information is true.							
_							
Date:			Server's signature				
			Printed name and title				
			Server's address				

Additional information regarding attempted service, etc: